RecruitingNCT06844032
Predictors of Poor Prognosis in HFpEF
Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure with Preserved Ejection Fraction
Sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Enrollment
400 participants
Start Date
Jan 31, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Eligibility
Min Age: 40 Years
Inclusion Criteria4
- Signed and data informed consent;
- New York Heart Association (NYHA) class II-III heart failure;
- Left ventricular ejection fraction \> 50%;
- Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Exclusion Criteria11
- Evidence of myocardial ischemia during stress echocardiography;
- Significant lesions of the main coronary arteries;
- Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
- Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
- Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);
- Primary pulmonary artery hypertension;
- Significant left-sided structural valve disease;
- Anemia (Hb \< 100 g/L);
- Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI);
- Non-cardiac conditions that complicate/exclude participation in the study;
- Exacerbation of heart failure less than 3 months prior to study entry.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06844032